Sonoma Pharmaceuticals
SNOA
14 hedge funds and large institutions have $85.2K invested in Sonoma Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
1.96% more ownership
Funds ownership: 0.11% → 2.07% (+2%)
7% less capital invested
Capital invested by funds: $91.7K → $85.2K (-$6.5K)
18% less funds holding
Funds holding: 17 → 14 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$61.9K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$53.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$19K |
| 4 |
Citigroup
New York
|
+$919 |
| 5 |
JP Morgan Chase
New York
|
+$704 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$41.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$18.4K |
| 3 |
Jane Street
New York
|
-$9.61K |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.16K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.21K |
SNOA Hedge Fund Activity: Q3 2024 in Review
14 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q3 2024, worth a combined $85.2K — down 7.1% from $91.7K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SNOA and 5 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $61.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $41.4K sold.
- 14 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q3 2024, down from 17 in Q2 2024.
- Funds reported $85.2K of Sonoma Pharmaceuticals stock for Q3 2024, down 7.1% quarter-over-quarter.
- 5 funds opened new Sonoma Pharmaceuticals positions in Q3 2024 and 8 closed out, a net change of -3 holders.
- The largest Sonoma Pharmaceuticals buyer in Q3 2024 was UBS Group, an estimated $61.9K added.
- The largest Sonoma Pharmaceuticals seller in Q3 2024 was Citadel Advisors, an estimated $41.4K sold.
Based on aggregated 13F filings for Q3 2024.